J Pediatr Intensive Care 2020; 09(02): 135-138
DOI: 10.1055/s-0039-3401008
Case Report
Georg Thieme Verlag KG Stuttgart · New York

All in Your Mind? New-Onset Dysphagia in a Previously Healthy Adolescent Child

1   VCU Department of Pediatric Critical Care, Richmond, Virginia, United States
,
Douglas Willson
1   VCU Department of Pediatric Critical Care, Richmond, Virginia, United States
,
Mark Marinello
1   VCU Department of Pediatric Critical Care, Richmond, Virginia, United States
› Author Affiliations
Funding No funding was secured for this study. The authors have no financial relationships relevant to this article to disclose
Further Information

Publication History

03 September 2019

03 November 2019

Publication Date:
05 December 2019 (online)

Abstract

A healthy 11-year-old male develops fear of choking secondary to progressive dysphagia that began in early childhood. No organic cause is found, and the patient is diagnosed with psychiatric oral aversion. The child is eventually transferred to a psychiatric facility, where a month later he has a possible aspiration event and is transferred to the local emergency room for respiratory distress before being admitted to the intensive care unit. Workup is notable for abnormal findings on brain imaging, and the diagnosis of Alexander's disease is made. This case highlights the importance of complete history-taking and examinations in pediatric patients.

Authors' Contribution

This report was conceived by J.S. and D.W., with data collection, chart review, and literature review performed by J.S. The manuscript was written by J.S., with critical review by D.W. Both the authors approved the final manuscript and agree to be accountable for all aspects of the work.


 
  • References

  • 1 Messing A, Brenner M, Feany MB, Nedergaard M, Goldman JE. Alexander disease. J Neurosci 2012; 32 (15) 5017-5023
  • 2 Rodriguez D, Gauthier F, Bertini E. , et al. Infantile Alexander disease: spectrum of GFAP mutations and genotype-phenotype correlation. Am J Hum Genet 2001; 69 (05) 1134-1140
  • 3 Yoshida T, Nakagawa M. Clinical aspects and pathology of Alexander disease, and morphological and functional alteration of astrocytes induced by GFAP mutation. Neuropathology 2012; 32 (04) 440-446
  • 4 van der Knaap MS, Naidu S, Breiter SN. , et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22 (03) 541-552
  • 5 van der Knaap MS, Salomons GS, Li R. , et al. Unusual variants of Alexander's disease. Ann Neurol 2005; 57 (03) 327-338
  • 6 Barreau P, Prust MJ, Crane J, Loewenstein J, Kadom N, Vanderver A. Focal central white matter lesions in Alexander disease. J Child Neurol 2011; 26 (11) 1422-1424
  • 7 Prust M, Wang J, Morizono H. , et al. GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology 2011; 77 (13) 1287-1294
  • 8 Srivastava S, Naidu S. Alexander disease. In: Adam MP, Ardinger HH, Pagon RA. , et al., eds. GeneReviews®. Seattle (WA): University of Washington; 1993. http://www.ncbi.nlm.nih.gov/books/NBK1172/ . Accessed July 20, 2019
  • 9 Olabarria M, Putilina M, Riemer EC, Goldman JE. Astrocyte pathology in Alexander disease causes a marked inflammatory environment. Acta Neuropathol 2015; 130 (04) 469-486
  • 10 Ishigaki K, Ito Y, Sawaishi Y. , et al. TRH therapy in a patient with juvenile Alexander disease. Brain Dev 2006; 28 (10) 663-667
  • 11 Sechi G, Matta M, Deiana GA. , et al. Ceftriaxone has a therapeutic role in Alexander disease. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34 (02) 416-417
  • 12 Staba MJ, Goldman S, Johnson FL, Huttenlocher PR. Allogeneic bone marrow transplantation for Alexander's disease. Bone Marrow Transplant 1997; 20 (03) 247-249
  • 13 Brenner M, Goldman JE, Quinlan RA, Messing A. Alexander disease: a genetic disorder of astrocytes. In: Haydon PG, Parpura V. , eds. Astrocytes in (Patho)Physiology of the Nervous System. Boston, MA: Springer US; 2009: 591-648 . Doi: 10.1007/978-0-387-79492-1_24
  • 14 Meikle L, Pollizzi K, Egnor A. , et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008; 28 (21) 5422-5432
  • 15 Ravikumar B, Vacher C, Berger Z. , et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36 (06) 585-595
  • 16 Tang G, Yue Z, Talloczy Z. , et al. Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/MAPK and mTOR signaling pathways. Hum Mol Genet 2008; 17 (11) 1540-1555
  • 17 Tang G, Perng MD, Wilk S, Quinlan R, Goldman JE. Oligomers of mutant glial fibrillary acidic protein (GFAP) Inhibit the proteasome system in alexander disease astrocytes, and the small heat shock protein alphaB-crystallin reverses the inhibition. J Biol Chem 2010; 285 (14) 10527-10537